Apotex Reports Second-Quarter Results and Raises FY2027 Guidance
Apotex reported adjusted EBITDA of $280 million with a 33% margin. It raised its FY2027 outlook to about 9–10% revenue growth and about a 31% adjusted EBITDA margin.
Story updates
10:59:56 AM UTC
SquawkNews
Apotex reported Q2 revenue growth of 5% and Adjusted EBITDA growth of 19%; it raised FY2027 guidance to approximately 9—10% revenue growth and approximately 31% Adjusted EBITDA margin. The release gives no prior guidance for comparison.Material DetailsContext by AI AnalystThe raised FY2027 outlook…
Canada Leads with 14% Revenue Growth— Adjusted EBITDA1 of $280 Million with 33% Margin— Strong Execution Supports FY 2027 Guidance Upgrade: ~9-10% Revenue Growth and ~ 31% Adjusted EBITDA MarginTORONTO, Nov. 12, 2026 // -- Apotex Health Corp. ("Apotex" or the "Company") (TSX:APTX), a Ca…